The role of patient-reported outcomes in outpatients receiving active anti-cancer treatment: impact on patients' quality of life

被引:30
作者
Baratelli, Chiara [1 ,2 ,3 ]
Turco, Carmela Giovanna Cleopatra [1 ,2 ]
Lacidogna, Gaetano [1 ]
Sperti, Elisa [1 ]
Vignani, Francesca [1 ]
Marino, Donatella [1 ,2 ]
Zichi, Clizia [1 ,2 ]
De Luca, Emmanuele [1 ,2 ]
Audisio, Marco [1 ,2 ]
Ballaminut, Daniela [1 ]
Bellezza, Annalisa [1 ]
Chiotto, Paola [1 ]
Ciriolo, Giovanna [1 ]
Comite, Rossella [1 ]
Codegone, Fulvia [1 ]
Florio, Santina [1 ]
Fusco, Luisa [1 ]
Polimeno, Laura [1 ]
Pozzi, Donatella [1 ]
Zilio, Eliana [1 ]
Terzolo, Sabrina [1 ]
Di Maio, Massimo [1 ,2 ]
机构
[1] Ordine Mauriziano Hosp, Div Med Oncol, Turin, Italy
[2] Univ Turin, Dept Oncol, Via Magellano 1, I-10128 Turin, Italy
[3] San Luigi Gonzaga Hosp, Div Med Oncol, Orbassano, TO, Italy
关键词
Patient-reported outcomes; Quality of life; Side effects; Toxicity; COMMON TERMINOLOGY CRITERIA; CLINICAL-PRACTICE; ADVERSE EVENTS; IMPLEMENTATION; TOXICITIES; CARE;
D O I
10.1007/s00520-019-04777-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Patient-reported outcomes (PROs) are the gold standard to describe subjective symptoms. Nurses can be successfully involved in collecting symptom information, because of their direct relationship with the patient. In order to improve clinical management of outpatients receiving active anti-cancer treatment, we introduced in routine clinical practice an assessment of patient-reported symptoms and toxicities, starting from January 2018. Our hypothesis was that this could help to better control symptoms, improving patients' quality of life (QoL). Methods Eligible patients were receiving an active anti-cancer treatment, as outpatients. Patients included in the control group (treated in 2017) underwent "usual" visits (group A), while patients treated in 2018, before each visit received a questionnaire by a dedicated nurse, in order to provide information about symptoms and toxicities (group B). Primary objective was the comparison of QoL changes, measured by EORTC QLQ-C30. Results A total of 211 patients have been analyzed (119 group A; 92 group B). After 1 month, mean change from baseline of global QoL was - 1.68 in group A and + 2.54 in group B (p = 0.004, effect size 0.20). Group B showed significantly better mean changes for fatigue, pain, and appetite loss. Proportion of patients obtaining a clinically significant improvement in global QoL score was higher in group B (32.6%) compared to group A (19.3%, p = 0.04). Patients' satisfaction with questionnaire was high. Conclusion Introduction of PROs in clinical practice, thanks to an active role of nurses, was feasible, produced high patients' satisfaction and a significant QoL improvement, compared to the traditional modality of visit.
引用
收藏
页码:4697 / 4704
页数:8
相关论文
共 23 条
  • [1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY
    AARONSON, NK
    AHMEDZAI, S
    BERGMAN, B
    BULLINGER, M
    CULL, A
    DUEZ, NJ
    FILIBERTI, A
    FLECHTNER, H
    FLEISHMAN, SB
    DEHAES, JCJM
    KAASA, S
    KLEE, M
    OSOBA, D
    RAZAVI, D
    ROFE, PB
    SCHRAUB, S
    SNEEUW, K
    SULLIVAN, M
    TAKEDA, F
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) : 365 - 376
  • [2] [Anonymous], BEHALF EORTC QUALITY
  • [3] [Anonymous], 2006, COMMON TERMINOLOGY C
  • [4] [Anonymous], 2005, REFL PAP REG GUID US
  • [5] Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study
    Basch, Ethan
    Iasonos, Alexia
    McDonough, Tiffani
    Barz, Allison
    Culkin, Ann
    Kris, Mark G.
    Scher, Howard I.
    Schrag, Deborah
    [J]. LANCET ONCOLOGY, 2006, 7 (11) : 903 - 909
  • [6] Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
    Basch, Ethan
    Deal, Allison M.
    Dueck, Amylou C.
    Scher, Howard I.
    Kris, Mark G.
    Hudis, Clifford
    Schrag, Deborah
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (02): : 197 - 198
  • [7] Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
    Basch, Ethan
    Deal, Allison M.
    Kris, Mark G.
    Scher, Howard I.
    Hudis, Clifford A.
    Sabbatini, Paul
    Rogak, Lauren
    Bennett, Antonia V.
    Dueck, Amylou C.
    Atkinson, Thomas M.
    Chou, Joanne F.
    Dulko, Dorothy
    Sit, Laura
    Barz, Allison
    Novotny, Paul
    Fruscione, Michael
    Sloan, Jeff A.
    Schrag, Deborah
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) : 557 - +
  • [8] Use of Patient-Reported Outcomes to Improve the Predictive Accuracy of Clinician-Reported Adverse Events
    Basch, Ethan
    Bennett, Antonia
    Pietanza, M. Catherine
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (24) : 1808 - 1810
  • [9] A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting
    Chen, Jack
    Ou, Lixin
    Hollis, Stephanie J.
    [J]. BMC HEALTH SERVICES RESEARCH, 2013, 13
  • [10] Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire
    Cirillo, M.
    Venturini, M.
    Ciccarelli, L.
    Coati, F.
    Bortolami, O.
    Verlato, G.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (12) : 1929 - 1935